THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE

Objective: To assess clinical presentation and outcome of patients with thrombotic thrombocytopenic purpura (TTP) in our setup. Study Design: Descriptive study. Place and Duration of Study: Combined Military Hospital (CMH) Peshawar, from Feb 2016 to Aug 2017. Patients and Methods: In a prospecti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zahid Farooq Baig, Aamir Farukh, Mumtaz Amir, Aslam Khan, Nadir Ali
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2018
Materias:	pakistan thrombotic microangiopathy plasmapheresis Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6f6f726701fe46bbb981d490d7273bf8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f6f726701fe46bbb981d490d7273bf8
record_format	dspace
spelling	oai:doaj.org-article:6f6f726701fe46bbb981d490d7273bf82021-12-01T02:52:00ZTHROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE0030-96482411-8842https://doaj.org/article/6f6f726701fe46bbb981d490d7273bf82018-10-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/2224/1931https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To assess clinical presentation and outcome of patients with thrombotic thrombocytopenic purpura (TTP) in our setup. Study Design: Descriptive study. Place and Duration of Study: Combined Military Hospital (CMH) Peshawar, from Feb 2016 to Aug 2017. Patients and Methods: In a prospective design, patients diagnosed to be suffering from TTP, were included in this study. Detailed history along with physical examination and thorough investigation of all cases was carried out and collected on proformas. The diagnosis of TTP in our study was done by demonstration of significant schistocytes (more than 1 percent) on peripheral blood film. The patients were treated with steroids and plasma pheresis and in some cases with weekly Rituximab for 4 weeks. The patients were followed up in outdoor clinic on monthly basis. Results: Being a very rare disease, only 11 patients suffering from TTP reported during the study period. They were followed prospectively with a mean duration of follow-up of 11.23 months (± SD 5.57). All patients (100 percent) had anaemia, thrombocytopenia and acute kidney injury. Fever was seen in 54.4% patients and 63.6% patients had neurological involvement. A likely secondary cause of precipitation of TTP was found in 54.5% cases. The mortality rate was 18.2 percent. Conclusion: TTP is a challenging disease for intensive care specialists and can be fatal without effective treatment. A high index of suspicion followed by early diagnosis and prompt treatment can save life. Documentation of deficiency of plasma ADAMTS13 activity is not essential for the diagnosis of TTP and plasmapheresis is the treatment of choice.Zahid Farooq BaigAamir FarukhMumtaz AmirAslam KhanNadir AliArmy Medical College Rawalpindiarticlepakistan thrombotic microangiopathyplasmapheresisMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 68, Iss 5, Pp 1066-1070 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	pakistan thrombotic microangiopathy plasmapheresis Medicine R Medicine (General) R5-920
spellingShingle	pakistan thrombotic microangiopathy plasmapheresis Medicine R Medicine (General) R5-920 Zahid Farooq Baig Aamir Farukh Mumtaz Amir Aslam Khan Nadir Ali THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
description	Objective: To assess clinical presentation and outcome of patients with thrombotic thrombocytopenic purpura (TTP) in our setup. Study Design: Descriptive study. Place and Duration of Study: Combined Military Hospital (CMH) Peshawar, from Feb 2016 to Aug 2017. Patients and Methods: In a prospective design, patients diagnosed to be suffering from TTP, were included in this study. Detailed history along with physical examination and thorough investigation of all cases was carried out and collected on proformas. The diagnosis of TTP in our study was done by demonstration of significant schistocytes (more than 1 percent) on peripheral blood film. The patients were treated with steroids and plasma pheresis and in some cases with weekly Rituximab for 4 weeks. The patients were followed up in outdoor clinic on monthly basis. Results: Being a very rare disease, only 11 patients suffering from TTP reported during the study period. They were followed prospectively with a mean duration of follow-up of 11.23 months (± SD 5.57). All patients (100 percent) had anaemia, thrombocytopenia and acute kidney injury. Fever was seen in 54.4% patients and 63.6% patients had neurological involvement. A likely secondary cause of precipitation of TTP was found in 54.5% cases. The mortality rate was 18.2 percent. Conclusion: TTP is a challenging disease for intensive care specialists and can be fatal without effective treatment. A high index of suspicion followed by early diagnosis and prompt treatment can save life. Documentation of deficiency of plasma ADAMTS13 activity is not essential for the diagnosis of TTP and plasmapheresis is the treatment of choice.
format	article
author	Zahid Farooq Baig Aamir Farukh Mumtaz Amir Aslam Khan Nadir Ali
author_facet	Zahid Farooq Baig Aamir Farukh Mumtaz Amir Aslam Khan Nadir Ali
author_sort	Zahid Farooq Baig
title	THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
title_short	THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
title_full	THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
title_fullStr	THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
title_full_unstemmed	THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
title_sort	thrombotic thrombocytopenic purpura: our clinical experience
publisher	Army Medical College Rawalpindi
publishDate	2018
url	https://doaj.org/article/6f6f726701fe46bbb981d490d7273bf8
work_keys_str_mv	AT zahidfarooqbaig thromboticthrombocytopenicpurpuraourclinicalexperience AT aamirfarukh thromboticthrombocytopenicpurpuraourclinicalexperience AT mumtazamir thromboticthrombocytopenicpurpuraourclinicalexperience AT aslamkhan thromboticthrombocytopenicpurpuraourclinicalexperience AT nadirali thromboticthrombocytopenicpurpuraourclinicalexperience
_version_	1718405908929708032

THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE

Ejemplares similares